Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin

Current Medical Research and Opinion

Volumn 26, Issue 1, 2010, Pages 191-201

  McAdam Marx, Carrie ^a   Yu, Junhua ^a   Bouchard, Jonathan ^b   Aagren, Mark ^b   Brixner, Diana I ^a  

^a UNIVERSITY OF UTAH   (United States)

^b NOVO NORDISK INC   (United States)

Author keywords

Hypoglycemic agents; Insulin detemir; Insulin glargine; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GLITAZONE DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; METFORMIN; SITAGLIPTIN; SULFONYLUREA; INSULIN;

ADULT; AGED; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG USE; FEMALE; GROUPS BY AGE; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME; CASE CONTROL STUDY; DOSE RESPONSE; RETROSPECTIVE STUDY;

CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RETROSPECTIVE STUDIES;

EID: 77649212619     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903432470     Document Type: Article

References (26)

1. Centers for Disease Control. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2005.pdf [Last accessed 14 February 2006]
2. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
3. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12 (Pubitemid 30609442)
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352:837-53
5. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am 2001;30:935-82 (Pubitemid 33055270)
6. Esposito K, Ciotola M, Maiorino MI, et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008; 149:531-9
7. Gerstein H, Yale J, Harris S, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23:736-42 (Pubitemid 44366071)
8. Dornhorst A, Luäddeke H, Sreenan S, et al. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract 2008;62: 659-65 (Pubitemid 351348041)
9. Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract 2007;77:1-15 (Pubitemid 46590471)
10. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27:1081-7 (Pubitemid 38579770)
11. Raccah D, Bretzel RG, Owens D, et al. When basal insulin therapy in type 2 diabetes mellitus is not enough -what next? Diabetes Metab Res Rev 2007; 23:257-64 (Pubitemid 46851465)
12. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000;23:639-43 (Pubitemid 30321544)
13. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16
14. Cavallucci S. The top 200. What's making waves in prescription sales. Pharm Pract 2006;22:44-9
15. Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metabol Res Rev 2009;25: 252-8
16. Hollander P, Cooper J, Bregnhoj J, et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008;30:1976-87
17. Yenigun M, Honka M. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study. Int J Clin Pract 2009; 63:425-32
18. Meneghini LF, Rosenberg KH, Koenen C, et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007;9:418-27 (Pubitemid 46502062)
19. Borah BJ, Darkow T, Bouchard J, et al. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clin Therapeut 2009;31:623-31
20. Lewis CC, Fiscella RG, Kosty T. Need for greater scrutiny of days supply values in DACON calculations. J Manag Care Pharm 2004;10:172-3
21. Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25: 330-6 (Pubitemid 41079631)
22. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996;156:259-64 (Pubitemid 26058476)
23. Asche CV, McAdam-Marx C, Shane-McWhorter L, et al. Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:638-45 (Pubitemid 352044293)
24. Oderda G, Lieberman M, Asche C, et al. Use of electronic medical record (EMR) data in outcomes research. Value Health 2007;10:A450-1
25. McAdam-Marx C, Bouchard J, Aagren M, et al. Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting. Diabetes Obes Metabol 2009;epub ahead of print:16 Sept, 2009
26. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20 (Pubitemid 38196703)